EndoChoice Holdings Inc. (NYSE:GI) shares dropped 2.9% on Friday . The company traded as low as $4.19 and last traded at $4.30, with a volume of 136,699 shares trading hands. The stock had previously closed at $4.43.

GI has been the topic of a number of research reports. Zacks Investment Research lowered EndoChoice Holdings from a “buy” rating to a “hold” rating in a report on Wednesday, August 3rd. JPMorgan Chase & Co. started coverage on EndoChoice Holdings in a research note on Wednesday, July 13th. They issued an “overweight” rating for the company. William Blair downgraded EndoChoice Holdings from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 4th. Finally, Stifel Nicolaus cut their target price on EndoChoice Holdings from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, August 4th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $7.42.

The stock has a 50 day moving average price of $4.29 and a 200 day moving average price of $4.71. The company’s market capitalization is $112.00 million.

EndoChoice Holdings (NYSE:GI) last released its earnings results on Wednesday, August 3rd. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $0.47. The company earned $19.30 million during the quarter, compared to analyst estimates of $20.67 million. EndoChoice Holdings had a negative net margin of 88.94% and a negative return on equity of 62.04%. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.01) EPS. On average, analysts anticipate that EndoChoice Holdings Inc. will post ($2.53) earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Paloma Partners Management Co acquired a new position in shares of EndoChoice Holdings during the second quarter worth $161,000. Emerald Acquisition Ltd. acquired a new position in shares of EndoChoice Holdings during the second quarter worth $215,000. Spark Investment Management LLC acquired a new position in shares of EndoChoice Holdings during the second quarter worth $318,000. Bridgeway Capital Management Inc. acquired a new position in shares of EndoChoice Holdings during the second quarter worth $368,000. Finally, State Street Corp raised its position in shares of EndoChoice Holdings by 46.7% in the first quarter. State Street Corp now owns 76,915 shares of the company’s stock worth $402,000 after buying an additional 24,500 shares in the last quarter. 37.71% of the stock is currently owned by hedge funds and other institutional investors.

EndoChoice Holdings Company Profile

EndoChoice Holdings, Inc is a medical device company. The Company is focused on designing and commercializing a platform of products and services for gastrointestinal (GI) caregivers. The Company offers a range of products and services that span single-use devices and infection control products, pathology and imaging systems.

5 Day Chart for NYSE:GI

Receive News & Ratings for EndoChoice Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EndoChoice Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.